Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010

Published: July 18, 2011

5 1.0 Introduction
6 1.1 Executive Summary
8 2.0 HIV Prevention R&D
8 2.1 Global Investments in HIV Vaccine R&D in 2010
9 2.1.1 Public Investments in HIV Vaccine R&D
12 2.1.2 Philanthropic Investments in HIV Vaccine R&D
12 2.1.3 Commercial Investments in HIV Vaccine R&D
14 2.1.4 Funding Allocations for HIV Vaccine R&D
15 2.1.5 Global Investments in Therapeutic HIV Vaccine R&D
16 2.2 Global Investments in Microbicide R&D
18 2.2.1 Public Investments in Microbicide R&D
19 2.2.2 Philanthropic Investments in Microbicide R&D
20 2.2.3 Commercial Investments in and Contributions to Microbicide R&D
21 2.2.4 Funding Allocations for Microbicide R&D
22 2.2.5 Investments in Rectal Microbicide R&D
22 2.3 Global Investments in R&D and Operations Research for Other
HIV Prevention Options
23 2.3.1 Investments in Follow-Up Studies and Operations Research
Related to Adult Male Circumcision
24 2.3.2 Investments in R&D Related to Pre-exposure Prophylaxis
25 2.3.3 Investments in R&D Related to Treatment as Prevention
27 2.3.4 Investments in R&D Related to HSV-2 Prevention
28 2.3.5 Investments in Operations Research Related to Vertical Transmission Prevention
30 2.3.6 Investments in R&D and Operations Research Related to Female Condoms
31 2.4 Investments by Trial Participants in HIV Prevention R&D
32 3.0 Discussion
36 Appendix: Methodology
38 Appendix: Commercial Sector Research Programs
39 List of Acronyms
40 Acknowledgements

Full text of article available at link below –

Leave a Reply